Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160626 · ClinicalTrials.gov registry record · Phase 2
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT02160626: Completed Phase 2 study, sponsored by Aclaris Therapeutics.
NCT02160626 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 172 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02160626, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
Primary Outcome
Mean of per-subject percentages of target lesions judged to be clear on the PLA (PLA = 0) at end of study (Visit 8). The PLA is a four point scale from 0 being clear to 3 being most severe lesion.
Interventions
- DRUG A-101 Vehicle
- DRUG A-101 (40) Topical Solution
- DRUG A-101 (32.5) Topical Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT02160626 record still lists
NCT02160626 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 3 interventions - of which A-101 Vehicle is the first listed.
NCT02160626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02160626 about?
NCT02160626 is a clinical study titled "Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis". The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
What is the current status of trial NCT02160626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02160626?
The interventions under investigation include: A-101 Vehicle (DRUG), A-101 (40) Topical Solution (DRUG), A-101 (32.5) Topical Solution (DRUG).
Who is sponsoring clinical trial NCT02160626?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02160626's enrollment target sits among peer trials
172 397th of 2000 higher than 1,603 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia